“Increased Emphasis on Genetic Screening and Immunological Management”
- A significant trend in the DiGeorge syndrome drug market is the growing focus on early genetic testing and targeted immunological therapies to address the multi-systemic manifestations of the disorder.
- Treatment regimens are evolving to include personalized care plans, including thymus transplantation, calcium supplementation, antipsychotic therapies, and prophylactic antibiotics for immune-compromised patients.
- For example, improved clinical guidelines now recommend chromosomal microarray testing and FISH (fluorescent in situ hybridization) as standard diagnostic tools for early detection of 22q11.2 deletion syndrome.
- Furthermore, multidisciplinary care involving cardiology, endocrinology, psychiatry, and immunology is being emphasized to optimize outcomes and manage long-term complications.
- The rising incidence of congenital heart defects, developmental delays, and immune deficiencies linked with DiGeorge syndrome is creating heightened awareness and demand for appropriate drug therapies.
